Pieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Performance

NASDAQ PIRS opened at $8.68 on Thursday. The firm’s 50 day moving average price is $10.32 and its two-hundred day moving average price is $12.55. Pieris Pharmaceuticals has a twelve month low of $8.31 and a twelve month high of $41.78. The stock has a market cap of $11.46 million, a price-to-earnings ratio of -0.73 and a beta of 0.68.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($3.95) earnings per share for the quarter. The business had revenue of $0.05 million for the quarter. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative return on equity of 57.57%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Summit Trail Advisors LLC purchased a new stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 140,000 shares of the biotechnology company’s stock, valued at approximately $26,000. Summit Trail Advisors LLC owned approximately 0.14% of Pieris Pharmaceuticals as of its most recent SEC filing. Institutional investors own 40.11% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.